PI3K Cancer Research Results

PI3K, Phosphatidylinositide-3-Kinases: Click to Expand ⟱
Source: HalifaxProj(inhibit) CGL-CS
Type:
Phosphatidylinositol 3-kinase (PtdIns3K or PI3K) is a family of enzymes that play a crucial role in cell signaling pathways, particularly in the regulation of cell growth, survival, and metabolism. The PI3K pathway is one of the most frequently altered pathways in human cancer. Inhibition of the PI3K pathway has been explored as a therapeutic strategy for cancer treatment. Several PI3K inhibitors have been developed and are currently being tested in clinical trials. These inhibitors can target specific components of the pathway, such as PI3K, AKT, or mTOR.

Class I phosphoinositide 3-kinase (PI3K)
Class III PtdIns3K
In contrast to the class III PtdIns3K as a positive regulator of autophagy, class I PI3K-AKT signaling has an opposing effect on the initiation of autophagy.

PI3K inhibitors include:
-Idelalisib , Copanlisib, Alpelisib
-LY294002?
-Wortmannin: potent PI3K inhibitor, has some associated toxicity.
-Quercetin:
-Curcumin
-Resveratrol
-Epigallocatechin Gallate (EGCG)


Scientific Papers found: Click to Expand⟱
1469- SFN,    Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis
- in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vivo, Pca, NA
eff↑, ROS↑, MMP↓, Casp3↑, Casp9↑, DR4↑, DR5↑, BAX↑, Bak↑, BIM↑, NOXA↑, Bcl-2↓, Bcl-xL↓, Mcl-1↓, eff↓, TumCG↓, TumCP↓, eff↑, NF-kB↓, PI3K↓, Akt↓, MEK↓, ERK↓, angioG↓, FOXO3↑,
1475- SFN,  Form,    Combination of Formononetin and Sulforaphane Natural Drug Repress the Proliferation of Cervical Cancer Cells via Impeding PI3K/AKT/mTOR Pathway
- in-vitro, Cerv, HeLa
TumCP↓, PI3K↓, Akt↓, mTOR↓, eff↑, ROS↑,
1513- SFN,  acetaz,    Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis
- in-vitro, BrCC, H720 - in-vivo, BrCC, NA - in-vitro, BrCC, H727
eff↑, tumCV↓, Apoptosis↑, P21↑, PI3K↓, Akt↓, mTOR↓, 5HT↓, NRF2↑,
4203- SIL,    Unlocking the Neuroprotective Potential of Silymarin: A Promising Ally in Safeguarding the Brain from Alzheimer’s Disease and Other Neurological Disorders
- Review, NA, NA
*MAPK↝, *AMPK↝, *NF-kB↓, *mTOR↝, *PI3K↝, *Akt↝, *BioAv↝, *memory↑, *BDNF↑, *TNF-α↓,
3323- SIL,    Anticancer therapeutic potential of silibinin: current trends, scope and relevance
- Review, Var, NA
Inflam↓, angioG↓, antiOx↑, TumMeta↓, TumCP↓, TumCCA↑, TumCD↑, α-SMA↓, p‑Akt↓, p‑STAT3↓, COX2↓, IL6↓, MMP2↓, HIF-1↓, Snail↓, Slug↓, Zeb1↓, NF-kB↓, p‑EGFR↓, JAK2↓, PI3K↓, PD-L1↓, VEGF↓, CDK4↓, CDK2↓, cycD1/CCND1↓, E2Fs↓,
3289- SIL,    Silymarin: a promising modulator of apoptosis and survival signaling in cancer
- Review, Var, NA
*BioAv↝, *BioAv↓, Fas↑, FasL↑, FADD↑, pro‑Casp8↑, Apoptosis↑, DR5↑, Bcl-2↑, BAX↑, Casp3↑, PI3K↓, FOXM1↓, p‑mTOR↓, p‑P70S6K↓, Hif1a↓, Akt↑, angioG↓, STAT3↓, NF-kB↓, lipid-P↓, eff↑, CDK1↓, survivin↓, CycB/CCNB1↓, Mcl-1↓, Casp9↑, AP-1↓, BioAv↑,
3288- SIL,    Silymarin in cancer therapy: Mechanisms of action, protective roles in chemotherapy-induced toxicity, and nanoformulations
- Review, Var, NA
Inflam↓, lipid-P↓, TumMeta↓, angioG↓, chemoP↑, EMT↓, HDAC↓, HATs↑, MMPs↓, uPA↓, PI3K↓, Akt↓, VEGF↓, CD31↓, Hif1a↓, VEGFR2↓, Raf↓, MEK↓, ERK↓, BIM↓, BAX↑, Bcl-2↓, Bcl-xL↓, Casp↑, MAPK↓, P53↑, LC3II↑, mTOR↓, YAP/TEAD↓, *BioAv↓, MMP↓, Cyt‑c↑, PCNA↓, cMyc↓, cycD1/CCND1↓, β-catenin/ZEB1↓, survivin↓, APAF1↑, Casp3↑, MDSCs↓, IL10↓, IL2↑, IFN-γ↑, hepatoP↑, cardioP↑, GSH↑, neuroP↑,
978- SIL,    A comprehensive evaluation of the therapeutic potential of silibinin: a ray of hope in cancer treatment
- Review, NA, NA
PI3K↓, Akt↓, NF-kB↓, Wnt/(β-catenin)↓, MAPK↓, TumCP↓, TumCCA↑, Apoptosis↑, p‑EGFR↓, JAK2↓, STAT5↓, cycD1/CCND1↓, hTERT/TERT↓, AP-1↓, MMP9↓, miR-21↓, miR-155↓, Casp9↑, BID↑, ERK↓, Akt2↓, DNMT1↓, P53↑, survivin↓, Casp3↑, ROS↑,
2415- SK,    Shikonin induces programmed death of fibroblast synovial cells in rheumatoid arthritis by inhibiting energy pathways
- in-vivo, Arthritis, NA
Apoptosis?, TumAuto↑, ROS↑, ATP↓, Glycolysis↓, PI3K↓, Akt↓, mTOR↓, *Apoptosis↓, *Inflam↓, *TNF-α↓, *IL6↓, *IL8↓, *IL10↓, *IL17↓, *hepatoP↑, *RenoP↑, PKM2↓, GLUT1↓, HK2↓,
2355- SK,    Pharmacological properties and derivatives of shikonin-A review in recent years
- Review, Var, NA
AntiCan↑, TumCP↓, TumCMig↓, Apoptosis↑, TumAuto↑, Necroptosis↑, ROS↑, TrxR1↓, PKM2↓, RIP1↓, RIP3↓, Src↓, FAK↓, PI3K↓, Akt↓, mTOR↓, GRP58↓, MMPs↓, ATF2↓, cl‑PARP↑, Casp3↑, p‑p38↑, p‑JNK↑, p‑ERK↓,
2370- SK,    The role of pyruvate kinase M2 in anticancer therapeutic treatments
- Review, Var, NA
Glycolysis↓, PKM2↓, EGFR↓, PI3K↓, p‑Akt↓, Hif1a↓,
2360- SK,    Shikonin inhibits growth, invasion and glycolysis of nasopharyngeal carcinoma cells through inactivating the phosphatidylinositol 3 kinase/AKT signal pathway
- in-vitro, NPC, HONE1 - in-vitro, NPC, SUNE-1
TumCP↓, Apoptosis↑, TumCMig↓, TumCI↓, GlucoseCon↓, lactateProd↓, ATP↓, PKM2↓, PI3K↓, Akt↓, MMP3↓, MMP9↓, TIMP1↑,
2194- SK,    Efficacy of Shikonin against Esophageal Cancer Cells and its possible mechanisms in vitro and in vivo
- in-vitro, ESCC, Eca109 - in-vitro, ESCC, EC9706 - in-vivo, NA, NA
tumCV↓, TumCCA↑, Apoptosis↑, EGFR↓, PI3K↓, Hif1a↓, PKM2↓, cycD1/CCND1↓, AntiTum↑,
2188- SK,    Molecular mechanism of shikonin inhibiting tumor growth and potential application in cancer treatment
- Review, Var, NA
ROS↑, EGFR↓, PI3K↓, Akt↓, angioG↓, Apoptosis↑, Necroptosis↑, GSH↓, Ca+2↓, MMP↓, ERK↓, p38↑, proCasp3↑, eff↓, VEGF↓, FOXO3↑, EGR1↑, SIRT1↑, RIP1↑, RIP3↑, BioAv↓, NF-kB↓, Half-Life↓,
2224- SK,    Shikonin induces apoptosis and autophagy via downregulation of pyrroline-5-carboxylate reductase1 in hepatocellular carcinoma cells
- in-vitro, HCC, SMMC-7721 cell - in-vitro, HCC, HUH7 - in-vitro, HCC, HepG2
PYCR1↓, PI3K↓, Akt↓, mTOR↓, eff↑,
2220- SK,    Shikonin Alleviates Gentamicin-Induced Renal Injury in Rats by Targeting Renal Endocytosis, SIRT1/Nrf2/HO-1, TLR-4/NF-κB/MAPK, and PI3K/Akt Cascades
- in-vivo, Nor, NA
*RenoP↑, *ROS↓, *SIRT1↓, *NRF2↑, *HO-1↑, *GSH↑, *TAC↑, *SOD↑, *MDA↓, *NO↓, *iNOS↓, *NHE3↑, *PI3K↑,
3043- SK,    Shikonin Induces Apoptosis by Inhibiting Phosphorylation of IGF-1 Receptor in Myeloma Cells.
- in-vitro, Melanoma, RPMI-8226
IGF-1↓, Apoptosis↑, TumCCA↑, MMP↓, Casp3↑, P53↑, BAX↑, Mcl-1↓, EGFR↓, Src↑, KDR/FLK-1↓, p‑IGF-1↓, PI3K↓, Akt↓,
5103- SK,    Attenuation of PI3K-Akt-mTOR Pathway to Reduce Cancer Stemness on Chemoresistant Lung Cancer Cells by Shikonin and Synergy with BEZ235 Inhibitor
- in-vitro, NSCLC, A549
CSCs↓, TumCP↓, Nanog↓, OCT4↓, p‑Akt↓, P70S6K↓, PI3K↓, mTOR↓, eff↑,
4216- SSE,    Selenium ameliorates mercuric chloride-induced brain damage through activating BDNF/TrKB/PI3K/AKT and inhibiting NF-κB signaling pathways
- in-vitro, NA, NA
*BDNF↑, *TrkB↓, *PI3K↑, *Akt↑, *neuroP↑,
5076- SSE,    Sodium selenite inhibits the growth of cervical cancer cells through the PI3K/AKT pathway
- in-vivo, Cerv, HeLa - in-vivo, Cerv, SiHa
TumCG↓, toxicity↓, tumCV↓, Apoptosis↑, p‑PI3K↓, p‑Akt↓, eff↑,
5110- SSE,    Autophagy inhibition through PI3K/Akt increases apoptosis by sodium selenite in NB4 cells
- in-vitro, AML, APL NB4
Apoptosis↑, selectivity↑, TumAuto↓, PI3K↓, Akt↓,
5331- TFdiG,    Anti-Cancer Properties of Theaflavins
- Review, Var, NA
AntiCan↑, TumCP↓, TumCMig↓, Apoptosis↑, cl‑PARP↑, cl‑Casp3↑, cl‑Casp7↑, cl‑Casp8↑, cl‑Casp9↑, BAX↑, Bcl-2↓, p‑Akt↓, p‑mTOR↓, PI3K↓, cMyc↓, P53↑, ROS↑, NF-kB↓, MMP9↓, MMP2↓, TumVol↓, PSA↓, TumCCA↑, VEGF↓, Hif1a↓, CDK2↓, CDK4↓, GSH↓, Dose↑, BioAv↓, BioAv↓, BioAv↑,
5336- TFdiG,    Theaflavin-3,3′-Digallate Protects Cartilage from Degradation by Modulating Inflammation and Antioxidant Pathways
- in-vivo, Nor, NA
*IL6↓, *TNF-α↓, *iNOS↓, *PGE1↓, *ROS↓, *Inflam↓, *PI3K↓, *Akt↓, *NF-kB↓, *MAPK↓, *Cartilage↑,
1019- TQ,    Thymoquinone suppresses migration of LoVo human colon cancer cells by reducing prostaglandin E2 induced COX-2 activation
- vitro+vivo, CRC, LoVo
TumCP↓, p‑PI3K↓, p‑Akt↓, p‑GSK‐3β↓, β-catenin/ZEB1↓, COX2↓, PGE2↓, EP2↓, EP4↓,
2127- TQ,    Therapeutic Potential of Thymoquinone in Glioblastoma Treatment: Targeting Major Gliomagenesis Signaling Pathways
- Review, GBM, NA
chemoP↑, ChemoSen↑, BioAv↑, PTEN↑, PI3K↓, Akt↓, TumCCA↓, NF-kB↓, p‑Akt↓, p65↓, XIAP↓, Bcl-2↓, COX2↓, VEGF↓, mTOR↓, RAS↓, Raf↓, MEK↓, ERK↓, MMP2↓, MMP9↓, TumCMig↓, TumCI↓, Casp↑, cl‑PARP↑, ROS⇅, ROS↑, MMP↓, eff↑, Telomerase↓, DNAdam↑, Apoptosis↑, STAT3↓, RadioS↑,
2138- TQ,    Thymoquinone has a synergistic effect with PHD inhibitors to ameliorate ischemic brain damage in mice
- in-vivo, Nor, NA
*Hif1a↑, *VEGF↑, *TrkB↑, *PI3K↑, *angioG↑, *neuroG↑, *motorD↑,
2084- TQ,    Thymoquinone, as an anticancer molecule: from basic research to clinical investigation
- Review, Var, NA
*ROS↓, *chemoPv↑, ROS↑, ROS⇅, MUC4↓, selectivity↑, AR↓, cycD1/CCND1↓, Bcl-2↓, Bcl-xL↓, survivin↓, Mcl-1↓, VEGF↓, cl‑PARP↑, ROS↑, HSP70/HSPA5↑, P53↑, miR-34a↑, Rac1↓, TumCCA↑, NOTCH↓, NF-kB↓, IκB↓, p‑p65↓, IAP1↓, IAP2↑, XIAP↓, TNF-α↓, COX2↓, Inflam↓, α-tubulin↓, Twist↓, EMT↓, mTOR↓, PI3K↓, Akt↓, BioAv↓, ChemoSen↑, BioAv↑, PTEN↑, chemoPv↑, RadioS↑, *Half-Life↝, *BioAv↝,
2106- TQ,    Cancer: Thymoquinone antioxidant/pro-oxidant effect as potential anticancer remedy
- Review, Var, NA
Apoptosis↑, TumCCA↑, ROS↑, *Catalase↑, *SOD↑, *GR↑, *GSTA1↓, *GPx↑, *H2O2↓, *ROS↓, *lipid-P↓, *HO-1↑, p‑Akt↓, AMPKα↑, NK cell↑, selectivity↑, Dose↝, eff↑, GSH↓, eff↓, P53↑, p‑STAT3↓, PI3K↑, MAPK↑, GSK‐3β↑, ChemoSen↑, RadioS↑, BioAv↓, NRF2↑,
1935- TQ,    Potential anticancer properties and mechanisms of thymoquinone in osteosarcoma and bone metastasis
- Review, OS, NA
Apoptosis↑, TumCCA↑, angioG↓, TumMeta↓, ROS↑, P53↑, Twist↓, E-cadherin↑, N-cadherin↓, NF-kB↓, IL8↓, XIAP↓, Bcl-2↓, STAT3↓, MAPK↓, PI3K↓, Akt↓, ERK↓, MMP2↓, MMP9↓, *ROS↓, HO-1↑, selectivity↑, TumCG↓,
3407- TQ,    Thymoquinone and its pharmacological perspective: A review
- Review, NA, NA
*antiOx↑, *ROS↓, *GSTs↑, *GSR↑, *GSH↑, *RenoP↑, *IL1β↓, *TNF-α↓, *MMP13↓, *COX2↓, *PGE2↓, *radioP↑, Twist↓, EMT↓, NF-kB↓, p‑PI3K↓, p‑Akt↓, p‑GSK‐3β↓, DNMT1↓, HDAC↓,
3397- TQ,    Thymoquinone: A Promising Therapeutic Agent for the Treatment of Colorectal Cancer
- Review, CRC, NA
ChemoSen↑, *Half-Life↝, *BioAv↝, *antiOx↑, *Inflam↓, *hepatoP↑, TumCP↓, TumCCA↑, Apoptosis↑, angioG↑, selectivity↑, JNK↑, p38↑, p‑NF-kB↑, ERK↓, PI3K↓, PTEN↑, Akt↓, mTOR↓, EMT↓, Twist↓, E-cadherin↓, ROS⇅, *Catalase↑, *SOD↑, *GSTA1↑, *GPx↑, *PGE2↓, *IL1β↓, *COX2↓, *MMP13↓, MMPs↓, TumMeta↓, VEGF↓, STAT3↓, BAX↑, Bcl-2↑, Casp9↑, Casp7↑, Casp3↑, cl‑PARP↑, survivin↓, cMyc↓, cycD1/CCND1↓, p27↑, P21↑, GSK‐3β↓, β-catenin/ZEB1↓, chemoP↑,
3425- TQ,    Advances in research on the relationship between thymoquinone and pancreatic cancer
Apoptosis↑, TumCP↓, TumCI↓, TumMeta↓, ChemoSen↑, angioG↓, Inflam↓, NF-kB↓, PI3K↓, Akt↓, TGF-β↓, Jun↓, p38↑, MAPK↑, MMP9↓, PKM2↓, ROS↑, JNK↑, MUC4↓, TGF-β↑, Dose↝, FAK↓, NOTCH↓, PTEN↑, mTOR↓, Warburg↓, XIAP↓, COX2↓, Casp9↑, Ki-67↓, CD34↓, VEGF↓, MCP1↓, survivin↓, Cyt‑c↑, Casp3↑, H4↑, HDAC↓,
3427- TQ,    Chemopreventive and Anticancer Effects of Thymoquinone: Cellular and Molecular Targets
ROS⇅, Fas↑, DR5↑, TRAIL↑, Casp3↑, Casp8↑, Casp9↑, P53↑, mTOR↓, Bcl-2↓, BID↓, CXCR4↓, JNK↑, p38↑, MAPK↑, LC3II↑, ATG7↑, Beclin-1↑, AMPK↑, PPARγ↑, eIF2α↓, P70S6K↓, VEGF↓, ERK↓, NF-kB↓, XIAP↓, survivin↓, p65↓, DLC1↑, FOXO↑, TET2↑, CYP1B1↑, UHRF1↓, DNMT1↓, HDAC1↓, IL2↑, IL1↓, IL6↓, IL10↓, IL12↓, TNF-α↓, iNOS↓, COX2↓, 5LO↓, AP-1↓, PI3K↓, Akt↓, cMET↓, VEGFR2↓, CXCL1↓, ITGA5↓, Wnt↓, β-catenin/ZEB1↓, GSK‐3β↓, Myc↓, cycD1/CCND1↓, N-cadherin↓, Snail↓, Slug↓, Vim↓, Twist↓, Zeb1↓, MMP2↓, MMP7↓, MMP9↓, JAK2↓, STAT3↓, NOTCH↓, cycA1/CCNA1↓, CDK2↓, CDK4↓, CDK6↓, CDC2↓, CDC25↓, Mcl-1↓, E2Fs↓, p16↑, p27↑, P21↑, ChemoSen↑,
3422- TQ,    Thymoquinone, as a Novel Therapeutic Candidate of Cancers
- Review, Var, NA
selectivity↑, P53↑, PTEN↑, NF-kB↓, PPARγ↓, cMyc↓, Casp↑, *BioAv↓, BioAv↝, eff↑, survivin↓, Bcl-xL↓, Bcl-2↓, Akt↓, BAX↑, cl‑PARP↑, CXCR4↓, MMP9↓, VEGFR2↓, Ki-67↓, COX2↓, JAK2↓, cSrc↓, Apoptosis↑, p‑STAT3↓, cycD1/CCND1↓, Casp3↑, Casp7↑, Casp9↑, N-cadherin↓, Vim↓, Twist↓, E-cadherin↑, ChemoSen↑, eff↑, EMT↓, ROS↑, DNMT1↓, eff↑, EZH2↓, hepatoP↑, Zeb1↓, RadioS↑, HDAC↓, HDAC1↓, HDAC2↓, HDAC3↓, *NAD↑, *SIRT1↑, SIRT1↓, *Inflam↓, *CRP↓, *TNF-α↓, *IL6↓, *IL1β↓, *eff↑, *MDA↓, *NO↓, *GSH↑, *SOD↑, *Catalase↑, *GPx↑, PI3K↓, mTOR↓,
3431- TQ,    PI3K-AKT Pathway Modulation by Thymoquinone Limits Tumor Growth and Glycolytic Metabolism in Colorectal Cancer
- in-vitro, CRC, HCT116 - in-vitro, CRC, SW48
Glycolysis↓, Warburg↓, HK2↓, ATP↓, NADPH↓, PI3K↓, Akt↓, TumCP↓, E-cadherin↑, N-cadherin↓, Hif1a↓, PKM2↓, GlucoseCon↓, lactateProd↓, EMT↓,
3423- TQ,    Epigenetic role of thymoquinone: impact on cellular mechanism and cancer therapeutics
- Review, Var, NA
AntiCan↑, Inflam↓, hepatoP↑, RenoP↑, BAX↑, Bak↑, Bcl-2↓, Bcl-xL↓, ROS↑, P53↑, PTEN↑, P21↑, p27↑, BRCA1↑, PI3K↓, Akt↓, MAPK↓, ERK↓, p‑ERK↓, MMPs↓, FAK↓, Twist↓, Zeb1↓, EMT↓, TumMeta↓, angioG↓, VEGF↓, HDAC↓, Maspin↑, SIRT1↑, DNMT1↓, DNMT3A↓, HDAC1↓, HDAC4↓,
3559- TQ,    Molecular signaling pathway targeted therapeutic potential of thymoquinone in Alzheimer’s disease
- Review, AD, NA - Review, Var, NA
*antiOx↑, *Inflam↓, *AChE↓, AntiCan↑, *cardioP↑, *RenoP↑, *neuroP↑, *hepatoP↑, TumCG↓, Apoptosis↑, PI3K↓, Akt↑, TumCCA↑, angioG↓, *NF-kB↓, *TLR2↓, *TLR4↓, *MyD88↓, *TRIF↓, *IRF3↓, *IL1β↓, *IL6↓, *IL12↓, *NRF2↑, *COX2↓, *VEGF↓, *MMP9↓, *cMyc↓, *cycD1/CCND1↓, *TumCP↓, *TumCI↓, *MDA↓, *TGF-β↓, *CRP↓, *Casp3↓, *GSH↑, *IL10↑, *iNOS↑, *lipid-P↓, *SOD↑, *H2O2↓, *ROS↓, *LDH↓, *Catalase↑, *GPx↑, *AChE↓, *cognitive↑, *MAPK↑, *JNK↑, *BAX↓, *memory↑, *Aβ↓, *MMP↑,
3573- TQ,    Chronic diseases, inflammation, and spices: how are they linked?
- Review, Var, NA
NF-kB↓, XIAP↓, PI3K↓, Akt↓, STAT3↓, JAK2↓, cSrc↓, PCNA↓, MMP2↓, ERK↓, Ki-67↓, Bcl-2↓, VEGF↓, p65↓, COX2↓, MMP9↓,
5020- UA,    Anticancer activity of ursolic acid on human ovarian cancer cells via ROS and MMP mediated apoptosis, cell cycle arrest and downregulation of PI3K/AKT pathway
- in-vitro, Ovarian, NA
tumCV↓, selectivity↑, BAX↑, Bcl-2↓, Apoptosis↑, ROS↑, TumCCA↑, Akt↓, PI3K↓,
4869- Uro,    Urolithin A in Central Nervous System Disorders: Therapeutic Applications and Challenges
- Review, AD, NA - Review, Park, NA - Review, Stroke, NA
*MitoP↑, *Inflam↓, *antiOx↑, *Risk↓, *Aβ↓, *p‑tau↓, *p62↓, *PARK2↑, *MMP↑, *ROS↓, *Strength↑, *CRP↓, *IL1β↓, *IL6↓, *TNF-α↓, *AMPK↑, *NF-kB↓, *MAPK↓, *p62↑, *NRF2↑, *SOD↑, *Catalase↑, *HO-1↑, *Ferroptosis↓, *lipid-P↓, *Cartilage↑, *PI3K↓, *Akt↓, *mTOR↓, *Apoptosis↓, *neuroP↑, *Bcl-2↓, *BAX↑, *Casp3↑, *ATP↑, *eff↑, *motorD↑, *NLRP3↓, *radioP↑, *BBB↑,
4862- Uro,    Neuroprotective effect of Urolithin A via downregulating VDAC1-mediated autophagy in Alzheimer's disease
- in-vivo, AD, NA - in-vitro, Nor, PC12
*cognitive↑, *p‑PI3K↓, *p‑Akt↓, *AMPK↑, *VDAC1↓, *neuroP↑, *PARK2↑, *PTEN↑, *LC3‑Ⅱ/LC3‑Ⅰ↑, *p62↓, *Aβ↓, *Apoptosis↓,
4833- Uro,    Unveiling the potential of Urolithin A in Cancer Therapy: Mechanistic Insights to Future Perspectives of Nanomedicine
- Review, Var, NA - Review, AD, NA - Review, IBD, NA
BioAv↝, TumAuto↝, TumCG↓, TumMeta↓, ChemoSen↑, Imm↑, RadioS↑, BioAv↑, other↝, eff↓, *antiOx↓, *Inflam↓, AntiCan↓, AntiAge↑, chemoP↑, *neuroP↑, *ROS↓, *cognitive↑, *lipid-P↓, *cardioP↑, *TNF-α↓, *IL6↓, GutMicro↑, TumCCA↑, Apoptosis↑, angioG↓, NF-kB↓, PI3K↓, Akt↓, Casp↑, survivin↓, TumCP↓, cycD1/CCND1↓, cMyc↑, BAX↑, Bcl-2↓, COX2↓, P53↑, p38↑, *ROS↓, *SOD↑, *GPx↑, SIRT1↑, FOXO1↑, eff↑, ChemoSen↑,
4837- Uro,    Urolithins: The Gut Based Polyphenol Metabolites of Ellagitannins in Cancer Prevention, a Review
- Review, Var, NA
AntiCan↑, TumCCA↑, Apoptosis↑, TumAuto↑, *BioAv↝, *BioAv↑, RAS↓, ERK↓, AR↓, TumCP↓, PI3K↓, Akt↓, NF-kB↓, COX2↓, IL6↓, IL1β↓, Wnt↓, β-catenin/ZEB1↓, cMyc↓, P53↑, Casp3↑, PARP↑, ROS↓, toxicity↓,
4853- Uro,    Urolithin A, a novel natural compound to target PI3K/AKT/mTOR pathway in pancreatic cancer
- vitro+vivo, PC, MIA PaCa-2 - in-vitro, NA, PANC1
p‑Akt↓, p‑p70S6↓, TumCG↓, OS↑, PI3K↓, mTOR↓, TumCP↓, TumCMig↓, Apoptosis↑, TAMS↓, Treg lymp↓, Wnt↓, IGF-1↓, *toxicity↓, *BioAv↑, Half-Life↝,
4855- Uro,    Urolithins impair cell proliferation, arrest the cell cycle and induce apoptosis in UMUC3 bladder cancer cells
- in-vitro, Bladder, UMUC3
TumCCA↑, PI3K↓, Akt↓, MAPK↓,
3135- VitC,    The interplay between vitamin C and thyroid
- Review, Thyroid, NA
AntiCan↑, ChemoSen↑, radioP↑, MAPK↓, ERK↓, PI3K↓, Akt↓, QoL↑, OS↑,
2365- VitD3,    Vitamin D Affects the Warburg Effect and Stemness Maintenance of Non- Small-Cell Lung Cancer Cells by Regulating the PI3K/AKT/mTOR Signaling Pathway
- in-vitro, Lung, A549 - in-vitro, Lung, H1975 - in-vivo, NA, NA
Glycolysis↓, Warburg↓, GLUT1↓, LDHA↓, HK2↓, PKM2↓, OCT4↓, SOX2↓, Nanog↓, PI3K↓, Akt↓, mTOR↓,
2283- VitK2,    Vitamin K Contribution to DNA Damage—Advantage or Disadvantage? A Human Health Response
- Review, Var, NA
*ER Stress↓, *toxicity↓, *toxicity↑, ROS↑, PI3K↑, Akt↑, Hif1a↑, GlucoseCon↑, lactateProd↑, ChemoSen↑, eff↑, eff↑,
2281- VitK2,    The biological responses of vitamin K2: A comprehensive review
- Review, Var, NA
*ROS↓, *12LOX↓, *NF-kB↓, *BMD↑, *hepatoP↑, cycD1/CCND1↓, PKCδ↓, STAT3↓, ERK↑, MAPK↓, ROS↑, PI3K↝, Akt↝, Hif1a↝, *neuroP↑,
1214- VitK2,    Vitamin K2 promotes PI3K/AKT/HIF-1α-mediated glycolysis that leads to AMPK-dependent autophagic cell death in bladder cancer cells
- in-vitro, Bladder, T24/HTB-9 - in-vitro, Bladder, J82
Glycolysis↑, GlucoseCon↑, lactateProd↑, TCA↓, PI3K↑, Akt↑, AMPK↑, mTORC1↓, TumAuto↑, GLUT1↑, HK2↑, LDHA↑, ACC↓, PDH↓, eff↓, cMyc↓, Hif1a↑, p‑Akt↑, eff↓, eff↓, eff↓, eff↓, ROS↑,

Showing Research Papers: 251 to 300 of 301
Prev Page 6 of 7 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 301

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress

antiOx↑, 1,   GSH↓, 3,   GSH↑, 1,   HO-1↑, 1,   lipid-P↓, 2,   NRF2↑, 2,   PYCR1↓, 1,   ROS↓, 1,   ROS↑, 19,   ROS⇅, 4,   TrxR1↓, 1,  

Mitochondria & Bioenergetics

ATP↓, 3,   CDC2↓, 1,   CDC25↓, 1,   MEK↓, 3,   MMP↓, 5,   Raf↓, 2,   XIAP↓, 6,  

Core Metabolism/Glycolysis

ACC↓, 1,   AMPK↑, 2,   ATG7↑, 1,   cMyc↓, 6,   cMyc↑, 1,   GlucoseCon↓, 2,   GlucoseCon↑, 2,   Glycolysis↓, 4,   Glycolysis↑, 1,   HK2↓, 3,   HK2↑, 1,   lactateProd↓, 2,   lactateProd↑, 2,   LDHA↓, 1,   LDHA↑, 1,   NADPH↓, 1,   PDH↓, 1,   PKM2↓, 8,   PPARγ↓, 1,   PPARγ↑, 1,   SIRT1↓, 1,   SIRT1↑, 3,   TCA↓, 1,   Warburg↓, 3,  

Cell Death

Akt↓, 28,   Akt↑, 4,   Akt↝, 1,   p‑Akt↓, 10,   p‑Akt↑, 1,   APAF1↑, 1,   Apoptosis?, 1,   Apoptosis↑, 22,   ATF2↓, 1,   Bak↑, 2,   BAX↑, 10,   Bcl-2↓, 12,   Bcl-2↑, 2,   Bcl-xL↓, 5,   BID↓, 1,   BID↑, 1,   BIM↓, 1,   BIM↑, 1,   Casp↑, 4,   Casp3↑, 11,   cl‑Casp3↑, 1,   proCasp3↑, 1,   Casp7↑, 2,   cl‑Casp7↑, 1,   Casp8↑, 1,   cl‑Casp8↑, 1,   pro‑Casp8↑, 1,   Casp9↑, 7,   cl‑Casp9↑, 1,   Cyt‑c↑, 2,   DR4↑, 1,   DR5↑, 3,   FADD↑, 1,   Fas↑, 2,   FasL↑, 1,   GRP58↓, 1,   hTERT/TERT↓, 1,   IAP1↓, 1,   IAP2↑, 1,   iNOS↓, 1,   JNK↑, 3,   p‑JNK↑, 1,   MAPK↓, 7,   MAPK↑, 3,   Mcl-1↓, 5,   Myc↓, 1,   Necroptosis↑, 2,   NOXA↑, 1,   p27↑, 3,   p38↑, 5,   p‑p38↑, 1,   RIP1↓, 1,   RIP1↑, 1,   survivin↓, 9,   Telomerase↓, 1,   TRAIL↑, 1,   TumCD↑, 1,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction

AMPKα↑, 1,   cSrc↓, 2,   p‑p70S6↓, 1,  

Transcription & Epigenetics

EZH2↓, 1,   H4↑, 1,   HATs↑, 1,   miR-21↓, 1,   other↝, 1,   tumCV↓, 4,  

Protein Folding & ER Stress

eIF2α↓, 1,   HSP70/HSPA5↑, 1,  

Autophagy & Lysosomes

Beclin-1↑, 1,   LC3II↑, 2,   TumAuto↓, 1,   TumAuto↑, 4,   TumAuto↝, 1,  

DNA Damage & Repair

BRCA1↑, 1,   CYP1B1↑, 1,   DNAdam↑, 1,   DNMT1↓, 5,   DNMT3A↓, 1,   p16↑, 1,   P53↑, 12,   PARP↑, 1,   cl‑PARP↑, 6,   PCNA↓, 2,   UHRF1↓, 1,  

Cell Cycle & Senescence

CDK1↓, 1,   CDK2↓, 3,   CDK4↓, 3,   cycA1/CCNA1↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 10,   E2Fs↓, 2,   P21↑, 4,   TumCCA↓, 1,   TumCCA↑, 14,  

Proliferation, Differentiation & Cell State

CD34↓, 1,   cMET↓, 1,   CSCs↓, 1,   EMT↓, 7,   EP2↓, 1,   EP4↓, 1,   ERK↓, 12,   ERK↑, 1,   p‑ERK↓, 2,   FOXM1↓, 1,   FOXO↑, 1,   FOXO1↑, 1,   FOXO3↑, 2,   GSK‐3β↓, 2,   GSK‐3β↑, 1,   p‑GSK‐3β↓, 2,   HDAC↓, 5,   HDAC1↓, 3,   HDAC2↓, 1,   HDAC3↓, 1,   HDAC4↓, 1,   IGF-1↓, 2,   p‑IGF-1↓, 1,   Jun↓, 1,   miR-34a↑, 1,   mTOR↓, 15,   p‑mTOR↓, 2,   mTORC1↓, 1,   Nanog↓, 2,   NOTCH↓, 3,   OCT4↓, 2,   P70S6K↓, 2,   p‑P70S6K↓, 1,   PI3K↓, 36,   PI3K↑, 3,   PI3K↝, 1,   p‑PI3K↓, 3,   PTEN↑, 6,   RAS↓, 2,   SOX2↓, 1,   Src↓, 1,   Src↑, 1,   STAT3↓, 7,   p‑STAT3↓, 3,   STAT5↓, 1,   TumCG↓, 6,   Wnt↓, 3,   Wnt/(β-catenin)↓, 1,  

Migration

5LO↓, 1,   Akt2↓, 1,   AP-1↓, 3,   Ca+2↓, 1,   CD31↓, 1,   DLC1↑, 1,   E-cadherin↓, 1,   E-cadherin↑, 3,   FAK↓, 3,   ITGA5↓, 1,   Ki-67↓, 3,   miR-155↓, 1,   MMP2↓, 6,   MMP3↓, 1,   MMP7↓, 1,   MMP9↓, 9,   MMPs↓, 4,   MUC4↓, 2,   N-cadherin↓, 4,   PKCδ↓, 1,   Rac1↓, 1,   RIP3↓, 1,   RIP3↑, 1,   Slug↓, 2,   Snail↓, 2,   TGF-β↓, 1,   TGF-β↑, 1,   TIMP1↑, 1,   Treg lymp↓, 1,   TumCI↓, 3,   TumCMig↓, 5,   TumCP↓, 15,   TumMeta↓, 7,   Twist↓, 7,   uPA↓, 1,   Vim↓, 2,   Zeb1↓, 4,   α-SMA↓, 1,   α-tubulin↓, 1,   β-catenin/ZEB1↓, 5,  

Angiogenesis & Vasculature

angioG↓, 10,   angioG↑, 1,   EGFR↓, 4,   p‑EGFR↓, 2,   EGR1↑, 1,   HIF-1↓, 1,   Hif1a↓, 6,   Hif1a↑, 2,   Hif1a↝, 1,   KDR/FLK-1↓, 1,   TAMS↓, 1,   VEGF↓, 11,   VEGFR2↓, 3,  

Barriers & Transport

GLUT1↓, 2,   GLUT1↑, 1,  

Immune & Inflammatory Signaling

COX2↓, 10,   CXCL1↓, 1,   CXCR4↓, 2,   IFN-γ↑, 1,   IL1↓, 1,   IL10↓, 2,   IL12↓, 1,   IL1β↓, 1,   IL2↑, 2,   IL6↓, 3,   IL8↓, 1,   Imm↑, 1,   Inflam↓, 5,   IκB↓, 1,   JAK2↓, 5,   MCP1↓, 1,   MDSCs↓, 1,   NF-kB↓, 16,   p‑NF-kB↑, 1,   NK cell↑, 1,   p65↓, 3,   p‑p65↓, 1,   PD-L1↓, 1,   PGE2↓, 1,   PSA↓, 1,   TNF-α↓, 2,  

Synaptic & Neurotransmission

5HT↓, 1,  

Hormonal & Nuclear Receptors

AR↓, 2,   CDK6↓, 1,  

Drug Metabolism & Resistance

BioAv↓, 5,   BioAv↑, 5,   BioAv↝, 2,   ChemoSen↑, 11,   Dose↑, 1,   Dose↝, 2,   eff↓, 9,   eff↑, 16,   Half-Life↓, 1,   Half-Life↝, 1,   RadioS↑, 5,   selectivity↑, 7,   TET2↑, 1,  

Clinical Biomarkers

AR↓, 2,   BRCA1↑, 1,   EGFR↓, 4,   p‑EGFR↓, 2,   EZH2↓, 1,   FOXM1↓, 1,   GutMicro↑, 1,   hTERT/TERT↓, 1,   IL6↓, 3,   Ki-67↓, 3,   Maspin↑, 1,   Myc↓, 1,   PD-L1↓, 1,   PSA↓, 1,  

Functional Outcomes

AntiAge↑, 1,   AntiCan↓, 1,   AntiCan↑, 6,   AntiTum↑, 1,   cardioP↑, 1,   chemoP↑, 4,   chemoPv↑, 1,   hepatoP↑, 3,   neuroP↑, 1,   OS↑, 2,   QoL↑, 1,   radioP↑, 1,   RenoP↑, 1,   toxicity↓, 2,   TumVol↓, 1,  
Total Targets: 311

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress

antiOx↓, 1,   antiOx↑, 4,   Catalase↑, 5,   Ferroptosis↓, 1,   GPx↑, 5,   GSH↑, 4,   GSR↑, 1,   GSTA1↓, 1,   GSTA1↑, 1,   GSTs↑, 1,   H2O2↓, 2,   HO-1↑, 3,   lipid-P↓, 4,   MDA↓, 3,   NRF2↑, 3,   PARK2↑, 2,   ROS↓, 11,   SOD↑, 7,   TAC↑, 1,   VDAC1↓, 1,  

Mitochondria & Bioenergetics

ATP↑, 1,   MMP↑, 2,  

Core Metabolism/Glycolysis

12LOX↓, 1,   AMPK↑, 2,   AMPK↝, 1,   cMyc↓, 1,   LDH↓, 1,   NAD↑, 1,   SIRT1↓, 1,   SIRT1↑, 1,  

Cell Death

Akt↓, 2,   Akt↑, 1,   Akt↝, 1,   p‑Akt↓, 1,   Apoptosis↓, 3,   BAX↓, 1,   BAX↑, 1,   Bcl-2↓, 1,   Casp3↓, 1,   Casp3↑, 1,   Ferroptosis↓, 1,   iNOS↓, 2,   iNOS↑, 1,   JNK↑, 1,   MAPK↓, 2,   MAPK↑, 1,   MAPK↝, 1,  

Protein Folding & ER Stress

ER Stress↓, 1,  

Autophagy & Lysosomes

LC3‑Ⅱ/LC3‑Ⅰ↑, 1,   MitoP↑, 1,   p62↓, 2,   p62↑, 1,  

Cell Cycle & Senescence

cycD1/CCND1↓, 1,  

Proliferation, Differentiation & Cell State

mTOR↓, 1,   mTOR↝, 1,   neuroG↑, 1,   PI3K↓, 2,   PI3K↑, 3,   PI3K↝, 1,   p‑PI3K↓, 1,   PTEN↑, 1,  

Migration

Cartilage↑, 2,   MMP13↓, 2,   MMP9↓, 1,   TGF-β↓, 1,   TumCI↓, 1,   TumCP↓, 1,  

Angiogenesis & Vasculature

angioG↑, 1,   Hif1a↑, 1,   NO↓, 2,   VEGF↓, 1,   VEGF↑, 1,  

Barriers & Transport

BBB↑, 1,   NHE3↑, 1,  

Immune & Inflammatory Signaling

COX2↓, 3,   CRP↓, 3,   IL10↓, 1,   IL10↑, 1,   IL12↓, 1,   IL17↓, 1,   IL1β↓, 5,   IL6↓, 6,   IL8↓, 1,   Inflam↓, 7,   MyD88↓, 1,   NF-kB↓, 5,   PGE1↓, 1,   PGE2↓, 2,   TLR2↓, 1,   TLR4↓, 1,   TNF-α↓, 7,   TRIF↓, 1,  

Synaptic & Neurotransmission

AChE↓, 2,   BDNF↑, 2,   p‑tau↓, 1,   TrkB↓, 1,   TrkB↑, 1,  

Protein Aggregation

Aβ↓, 3,   NLRP3↓, 1,  

Hormonal & Nuclear Receptors

GR↑, 1,  

Drug Metabolism & Resistance

BioAv↓, 3,   BioAv↑, 2,   BioAv↝, 5,   eff↑, 2,   Half-Life↝, 2,  

Clinical Biomarkers

BMD↑, 1,   CRP↓, 3,   IL6↓, 6,   LDH↓, 1,  

Functional Outcomes

cardioP↑, 2,   chemoPv↑, 1,   cognitive↑, 3,   hepatoP↑, 4,   memory↑, 2,   motorD↑, 2,   neuroP↑, 6,   radioP↑, 2,   RenoP↑, 4,   Risk↓, 1,   Strength↑, 1,   toxicity↓, 2,   toxicity↑, 1,  

Infection & Microbiome

IRF3↓, 1,  
Total Targets: 123

Scientific Paper Hit Count for: PI3K, Phosphatidylinositide-3-Kinases
18 Quercetin
16 Thymoquinone
12 Apigenin (mainly Parsley)
12 Fisetin
10 Berberine
10 Resveratrol
10 Shikonin
9 Baicalein
8 Carvacrol
8 Honokiol
7 Curcumin
7 Sulforaphane (mainly Broccoli)
6 Alpha-Lipoic-Acid
6 Luteolin
6 Magnolol
6 Rosmarinic acid
6 Urolithin
5 Cisplatin
5 Capsaicin
5 Chlorogenic acid
5 Chrysin
5 Lycopene
5 Silymarin (Milk Thistle) silibinin
4 5-fluorouracil
4 Astragalus
4 Carnosic acid
4 Propolis -bee glue
4 diet FMD Fasting Mimicking Diet
4 Ellagic acid
4 Magnetic Fields
4 Naringin
3 Silver-NanoParticles
3 Allicin (mainly Garlic)
3 Chemotherapy
3 Artemisinin
3 Astaxanthin
3 Bacopa monnieri
3 Thymol-Thymus vulgaris
3 Emodin
3 Selenite (Sodium)
3 Vitamin K2
2 Coenzyme Q10
2 Auranofin
2 Ashwagandha(Withaferin A)
2 Trastuzumab
2 Baicalin
2 Biochanin A
2 Betulinic acid
2 Brucea javanica
2 brusatol
2 Boswellia (frankincense)
2 Celecoxib
2 Citric Acid
2 Ursolic acid
2 EGCG (Epigallocatechin Gallate)
2 Ferulic acid
2 Gambogic Acid
2 Ginseng
2 Myricetin
2 Nimbolide
2 Piperine
2 Plumbagin
2 Parthenolide
2 Pterostilbene
2 Aflavin-3,3′-digallate
1 HydroxyCitric Acid
1 Acetyl-l-carnitine
1 Andrographis
1 Aspirin -acetylsalicylic acid
1 Ascorbyl Palmitate
1 Aloe anthraquinones
1 almonertinib
1 Berbamine
1 Bufalin/Huachansu
1 borneol
1 Caffeic acid
1 Caffeic Acid Phenethyl Ester (CAPE)
1 Celastrol
1 Dichloroacetophenone(2,2-)
1 Fucoidan
1 Gallic acid
1 Garcinol
1 Genistein (soy isoflavone)
1 Ginger/6-Shogaol/Gingerol
1 Hydrogen Gas
1 HydroxyTyrosol
1 Juglone
1 Licorice
1 Melatonin
1 Metformin
1 Magnetic Field Rotating
1 sericin
1 Phenethyl isothiocyanate
1 doxorubicin
1 Piperlongumine
1 Psoralidin
1 Radiotherapy/Radiation
1 Paclitaxel
1 Kaempferol
1 salinomycin
1 Sanguinarine
1 Selenium NanoParticles
1 Formononetin
1 acetazolamide
1 Vitamin C (Ascorbic Acid)
1 Vitamin D3
1 Wogonin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:252  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page